Galapagos NV (NASDAQ:GLPG)
| 139.86 BATS BZX Real-Time Price As of 10:30am ET |  -1.52 / -1.08%Today’s Change | 112.00 Today|||52-Week Range 274.03 | -32.38% Year-to-Date |
Latest GLPG News | Press Releases
| Amyris Patent Lawsuit, And Other News: The Good, Bad And Ugly Of Biopharma Sep 17 / Seeking Alpha - Paid Partner Content | Gilead Sciences Fails At Filgotinib - What's Next? Aug 20 / Seeking Alpha - Paid Partner Content |
| Galapagos (GLPG) Surges: Stock Moves 8.8% Higher Sep 14 / Zacks.com - Paid Partner Content | G1 Therapeutics' NDA Accepted, And Other News: The Alpha And Omega Of Biopharma Aug 20 / Seeking Alpha - Paid Partner Content |
| PTON, GLPG among premarket gainers Sep 11 / Seeking Alpha - Paid Partner Content | GRWG, MNTA, BMRN and VIPS among midday movers Aug 19 / Seeking Alpha - Paid Partner Content |
| Galapagos' Ziritaxestat successful in systemic sclerosis study Sep 11 / Seeking Alpha - Paid Partner Content | Momenta Pharmaceuticals leads healthcare gainers; Eyenovia and Galapagos among losers Aug 19 / Seeking Alpha - Paid Partner Content |
| Galapagos downgraded to Hold at Jefferies Aug 25 / Seeking Alpha - Paid Partner Content | GLPG, TJX among premarket losers Aug 19 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 141.38 |
| Today’s open | 139.68 |
| Day’s range | 139.27 - 140.01 |
| Volume | 1,175 |
| Average volume (3 months) | 130,813 |
| Market cap | $8.9B |
Data as of 10:26am ET, 09/18/2020
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -242.60% |
| Earnings growth (next 5 years) | -181.22% |
| Revenue growth (last year) | +177.55% |
| P/E ratio | 69.5 |
| Price/Sales | 13.15 |
| Price/Book | 2.74 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MYLMylan NV | -0.24 | -1.49% |
| JAZZJazz Pharmaceuticals... | +2.83 | +2.02% |
| RGENRepligen Corp | -0.06 | -0.04% |
| RDYDr.Reddy's Laborator... | +5.97 | +8.97% |
Data as of 10:32am ET, 09/18/2020
Financials
| Next reporting date | November 5, 2020 |
| EPS forecast (this quarter) | -$1.90 |
| Annual revenue (last year) | $945.7M |
| Annual profit (last year) | $167.7M |
| Net profit margin | 17.73% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Mechelen, Brussels Region |
Forecasts
